副腎原発CD5陽性CD10陽性びまん性大細胞型B細胞リンパ腫

山本 宜和; 住居 優一; 白石 雄太郎; 池内 一廣; 山田 晴士; 新谷 大悟; 塩手 康弘; 山本 和彦; 今城 健二

doi:10.11406/rinketsu.58.161

Short Reports

Primary adrenal diffuse large B-cell lymphoma positive for CD5 and CD10

Yoshikazu YAMAMOTO, Yuichi SUMII, Yutaro SHIRAISHI, Kazuhiro IKEUCHI, Haruto YAMADA, Daigo NIIYA, Yasuhiro SHIOTE, Kazuhiko YAMAMOTO, Kenji IMAJO

Author information

Yoshikazu YAMAMOTO
Department of Hematology and Oncology, Okayama City Hospital
Yuichi SUMII
Department of Hematology and Oncology, Okayama City Hospital
Yutaro SHIRAISHI
Department of Hematology and Oncology, Okayama City Hospital
Kazuhiro IKEUCHI
Department of Hematology and Oncology, Okayama City Hospital
Haruto YAMADA
Department of Clinical Laboratory, Okayama City Hospital
Daigo NIIYA
Department of Hematology and Oncology, Okayama City Hospital
Yasuhiro SHIOTE
Department of Hematology and Oncology, Okayama City Hospital
Kazuhiko YAMAMOTO
Department of Hematology and Oncology, Okayama City Hospital
Kenji IMAJO
Department of Hematology and Oncology, Okayama City Hospital

Keywords: CD5- and CD10-positive primary adrenal diffuse large B-cell lymphoma, EPOCH, Rituximab

JOURNAL RESTRICTED ACCESS

2017 Volume 58 Issue 2 Pages 161-164

DOI https://doi.org/10.11406/rinketsu.58.161

Details

Abstract

A 69-year-old man presented with back pain over the prior few months and was hospitalized because of bilateral adrenal masses and fracture of the left sixth rib. The mass on the right measured 6.5×3.6×7.0 cm, that on the left 8.1×4.8×6.9 cm, on CT. The final diagnosis was CD5- and CD10-positive primary adrenal diffuse large B-cell lymphoma (PA-DLBCL) with rib involvement. After EPOCH therapy accompanied with rituximab and intrathecal treatment, the tumors decreased dramatically. However, he died due to disease progression 8 months after the diagnosis. The prognosis of CD5- and CD10-positive PA-DLBCL may be very poor even with rituximab-containing chemotherapy.

Corresponding author

Register with J-STAGE for free!